- Home
- ICCM vs INCR Comparison
ICCM vs INCR Comparison
Compare ICCM & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | INCR |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 50.4M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICCM | INCR |
|---|---|---|
| Price | $0.58 | $0.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 175.1K | 54.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | $69.54 |
| Revenue Next Year | $31.38 | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.68 |
| 52 Week High | $1.53 | $1.77 |
Technical Indicators
Market Signals| Indicator | ICCM | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 40.76 |
| Support Level | $0.54 | $0.76 |
| Resistance Level | $0.74 | $0.98 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 26.94 | 38.70 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.